Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (17334)	3/12/1998 4:49:00 PM
From: WTDEC	Respond to of 32384

Henry, Deutche Morgan Grenfell recently joined those of us here who feel a period where biotechs will out-perform the market has begun. In a report dated March 9, Dr. Alex To writes "Despit the relatively strong performance of the biotechnology group year-to-date, and with 5 out of 6 stocks in our initial coverage posting over 10% gains, we believe that the group will continue to outperform the market. The fundamental driver of our optimism is the fact that the industry is acquiring critical mass. More that 20 new biotech products could reach the market this year -- more than the total number of new products introduced by the biotech industry in the past 25 years. We anticipate that these new product introductions will provide additional momentum for the biotech industry." I think Dr. To in new there and he is only following the large cap bts now, but I got the feeling from the report he plans to add some smaller companies. In any case, it is a plus for bts in general that DMG is now covering the sector. Regards, Walter